• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

I'm Going to Keep Riding These Horses

Biogen miss no reason to abandon big 4 of Big Pharma.
By JIM CRAMER Apr 24, 2015 | 11:22 AM EDT
Stocks quotes in this article: TWTR, BIIB, CELG, GILD, REGN, BMY, MRK, ABBV

Back away from the Four Horsemen? Are you nuts?

Some are questioning on Twitter (TWTR) whether the Biogen (BIIB) quarter miss this morning is enough to have me abandon ship on one of the key Four Horsemen: Biogen, Celgene (CELG), Gilead (GILD) and Regeneron (REGN) that I wrote about in Get Rich Carefully. While all of these stocks have appreciated well beyond when I was writing the book, the idea that an earnings miss from Biogen -- chiefly because of Tecfidera, an anti-MS formulation -- could have me back away from this company is ludicrous. I actually like it for its Alzheimer's possibilities, and while I don't deny disappointment in the MS drug's numbers, I can't abandon ship ahead of what might be one of the next big blockbusters.

Similarly, I see Celgene going higher off rumors that Bristol-Myers (BMY) might be buying it. I find this a little illogical -- they are about the same size! However, a merger of equals could make sense because they both have fabulous anti-cancer franchises. All that said, I like Celgene on earnings alone, especially when I hear about patent challenges against its key Revlimid drug. The patent seems pretty unassailable to me.

Gilead? I don't like additional competition coming into the hepatitis-C space, and that's what it has as of this morning when we learned that Merck's (MRK) got a new drug joining the fray to compete with Gilead and AbbVie (ABBV). That said, Gilead's got enough money from its initial monopoly off its miraculous blockbuster that it can reinvent itself and be worth a lot more than it's selling for, which is about half of the market multiple to the S&P 500.

Finally, there's Regeneron, which is rallying today because it turns out the company might have a revolutionary anti-muscular-aging compound, for which it just reported encouraging Phase 1 results. Now Phase 1 is really early. But who knew it was even working on this? That means it has a novel anti-cholesterol drug on the way, a potential anti-asthma drug and this, in addition to the amazing strength and superiority of its Eylea drug for macular degeneration of the eyes.

Now, one could argue that I am being piggish on all three. After all, I have been recommending Regeneron since it was at $5 and have been pushing Celgene forever and Gilead ever since we saw preliminary signs of the importance of its Pharmasset merger to its future. That's the company that produced its hep-C cure. Biogen's always seemed cheap to me, given its inventive nature and its amazing MS franchise, which isn't damaged in the least by the shortfall this morning, at least in my eyes. The Alzheimer's news did send the stock up 100 points, but I think it could go up huge again on any additional positive data.

So, I am sticking by the stocks of the Four Horsemen of the Big Pharma Apocalypse even up here. There's still too much upside to back down now.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long MRK and TWTR.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

CVS Stock Needs to Refill Its Prescription

Bruce Kamich
Mar 29, 2022 12:01 PM EDT

Charts are looking 'toppy' right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login